Loading: 100%
ALEXION PHARMACEUTICALS INC logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter Cheshire, United States of AmericaCheshire, United States of Americano data available
Employees 3,121 (as per Q1 2017)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker ALXNno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 1780100120140160
datesClosing price (adj.)
13.10.2017140.61
11.10.2017141.23
04.10.2017141.93
27.09.2017139.45
20.09.2017142.92
13.09.2017146.46
06.09.2017145.12
30.08.2017138.45
23.08.2017135.67
16.08.2017136.55
09.08.2017136.85
02.08.2017137.97
26.07.2017131.07
19.07.2017127.30
12.07.2017124.94
05.07.2017125.05
27.06.2017122.11
20.06.2017119.05
13.06.2017108.00
06.06.2017101.47
30.05.201797.78
23.05.2017104.64
16.05.2017120.30
09.05.2017124.67
02.05.2017133.41
25.04.2017120.55
18.04.2017118.22
11.04.2017116.89
04.04.2017118.30
28.03.2017118.53
21.03.2017118.70
14.03.2017121.60
07.03.2017129.18
28.02.2017131.25
21.02.2017129.89
14.02.2017129.50
07.02.2017127.72
31.01.2017130.68
24.01.2017129.87
17.01.2017135.30
10.01.2017143.67
03.01.2017122.63
27.12.2016126.06
19.12.2016114.56
12.12.2016115.08
05.12.2016124.93
28.11.2016119.38
21.11.2016117.68
14.11.2016118.89
07.11.2016120.05
31.10.2016130.50
24.10.2016121.61
17.10.2016119.47
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
140.61n/a
Market Capitalisation
in million USD
31,575n/a
Enterprise Value
in million USD
33,842n/a
Common Shares Outstanding
as per Apr 24, 2017
224,556,542n/a
Preferred Shares Outstanding
as per Apr 24, 2017
n/a
Average Basic Shares Outstanding
TTM
223,735,000n/a
Average Diluted Shares Outstanding
TTM
226,781,750n/a
Index Membership
n/a
Business Summary
Alexion Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
no data available
Key Financials & Ratios (all figures TTM as per Jun 30, 2016, million USD, full statements further below)
Profit & Loss
Revenues 2,822n/a
Gross Profit 2,590n/a
Operating Income 683n/a
EBITDA 1,021n/a
Net Profit 90n/a
Balance Sheet
Cash and Cash Equivalents 1,180n/a
Receivables 609n/a
Total Current Assets 2,361n/a
PP&E 825n/a
Total Assets 13,029n/a
Accounts Payable 29n/a
Current Debt 79n/a
Total Current Liabilities 658n/a
Long-Term Debt 3,368n/a
Total Liabilities 4,830n/a
Total Equity 8,199n/a
Cash Flow
Depreciation & Amortisation 338n/a
Change in Working Capital -450n/a
Operating Cash Flow 826n/a
Net Change in PP&E and Intangibles -287n/a
Investing Cash Flow -693n/a
Dividends Paid 0n/a
Financing Cash Flow -857n/a
Total Change in Cash -725n/a
Free Cash Flow -154n/a
Profitability Ratios
Gross Margin 91.8%n/a
Operating Margin 24.2%n/a
Net Profit Margin 3.2%n/a
Return on Equity 1.1%n/a
Return on Assets 0.7%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA 33.15n/a
EV/Sales 11.99n/a
Book to Market Value 0.26n/a
Other Ratios
Current Ratio 358.6%n/a
Liabilities to Equity Ratio 58.9%n/a
Debt to Assets Ratio 26.5%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Revenue
259
387
541
783
1,134
1,551
2,234
2,604
Sales & Services Revenue
259
387
541
783
1,134
1,551
2,234
2,603
Financing Revenue
0
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
2
Cost of revenue
-28
-45
-64
-93
-126
-168
-174
-233
Cost of Goods & Services
-28
-45
-64
-93
-126
-168
-174
-233
Cost of Financing Revenue
0
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
0
Gross Profit
231
342
477
690
1,008
1,383
2,060
2,371
Other Operating Income
0
0
0
0
0
0
0
0
Operating Expenses
-196
-255
-325
-446
-608
-807
-1,144
-1,689
Selling, General & Administrative
-134
-173
-227
-308
-385
-490
-630
-863
Selling & Marketing
0
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
0
Research & Development
-63
-82
-98
-137
-223
-317
-514
-709
Depreciation & Amortization
0
0
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
-117
Operating Income (Loss)
35
87
151
244
400
576
916
682
Non-Operating Income (Loss)
0
0
-2
-1
-7
-2
3
-39
Interest Expense, net
-2
-1
-1
-1
-7
-4
-3
-48
Interest Expense
0
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
0
Other Investment Income (Loss)
3
1
2
2
2
3
8
9
Foreign Exchange Gain (Loss)
0
-1
-2
-2
-1
-1
-2
1
Income (Loss) from Affiliates
0
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
0
0
0
0
0
Pretax Income (Loss), Adjusted
35
87
150
243
393
574
919
644
Abnormal Gains (Losses)
0
-3
-1
-13
4
-48
-47
-146
Acquired In-Process R&D
0
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
0
Pretax Income (Loss)
35
83
149
230
398
526
872
498
Income Tax (Expense) Benefit, net
-2
212
-52
-54
-143
-273
-215
-354
Current Income Tax
0
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
33
295
97
175
255
253
657
144
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
33
295
97
175
255
253
657
144
Minority Interest
0
0
0
0
0
0
0
0
Net Income
33
295
97
175
255
253
657
144
Preferred Dividends
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
33
295
97
175
255
253
657
144
Remarks
restated on Feb 17, 2011 n/a
calculated values,
restated on Feb 17, 2012 n/a
calculated values,
restated on Feb 19, 2013 n/a
calculated values,
restated on Feb 10, 2014 n/a
calculated values,
restated on Feb 6, 2015 n/a
calculated values,
restated on Feb 8, 2016 n/a
calculated values,
restated on Feb 8, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 96% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
176
362
541
990
1,515
1,962
1,385
Cash & Cash Equivalents
n/a
157
267
541
990
530
944
1,010
Short Term Investments
n/a
19
94
0
0
985
1,018
375
Accounts & Notes Receivable
n/a
114
169
244
296
422
433
533
Accounts Receivable, Net
n/a
114
169
244
296
422
433
533
Notes Receivable, Net
n/a
0
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
0
Inventories
n/a
41
62
81
95
103
176
290
Raw Materials
n/a
0
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
0
Other Short Term Assets
n/a
43
54
75
116
148
225
209
Prepaid Expenses
n/a
26
34
56
90
106
225
209
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
17
20
19
26
41
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
0
0
0
Total Current Assets
n/a
373
647
941
1,496
2,187
2,796
2,417
Property, Plant & Equipment, Net
n/a
165
162
166
166
201
392
697
Property, Plant & Equipment
n/a
0
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
0
0
0
0
0
0
0
Long Term Investments
n/a
0
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
0
Other Long Term Assets
n/a
248
203
288
952
930
1,014
9,984
Intangible Assets
n/a
29
24
92
647
610
587
4,708
Goodwill
n/a
20
20
80
254
254
254
5,048
Other Intangible Assets
n/a
0
0
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
194
155
104
14
3
0
0
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
5
5
13
38
63
173
228
Total Noncurrent Assets
n/a
413
365
453
1,118
1,131
1,406
10,681
Total Assets
n/a
786
1,012
1,395
2,614
3,318
4,202
13,098
Liabilities and owners' equity
Payables & Accruals
n/a
78 78445000
123 123056000
200 199653000
271 271275000
424 423940000
439 439248000
461 460708000
Accounts Payable
n/a
12 11530000
16 16026000
16 16029000
21 21488000
22 21596000
44 44016000
57 57360000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
67 66915000
107 107030000
184 183624000
250 249787000
402 402344000
395 395232000
403 403348000
Short Term Debt
n/a
0 422000
1 715000
0 0
48 48000000
48 48000000
48 48000000
166 166365000
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 422000
1 715000
0 0
48 48000000
48 48000000
48 48000000
166 166365000
Other Short Term Liabilities
n/a
6 6395000
15 14744000
28 28132000
41 40814000
110 110489000
119 119492000
83 82542000
Deferred Revenue
n/a
2 1652000
3 2896000
18 17905000
31 31266000
54 53801000
59 58837000
21 20504000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
5 4743000
12 11848000
10 10227000
10 9548000
57 56688000
61 60655000
62 62038000
Total Current Liabilities
n/a
85 85262000
139 138515000
228 227785000
360 360089000
582 582429000
607 606740000
710 709615000
Long Term Debt
n/a
10 10421000
4 4462000
0 0
101 101000000
97 97230000
117 116599000
3,406 3405843000
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
2 2362000
9 9324000
32 32474000
182 181621000
256 255958000
177 176605000
724 723807000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 204000
0 0
0 3000
20 19827000
101 101241000
7 7046000
529 528990000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
2 2158000
9 9324000
32 32471000
162 161794000
155 154717000
170 169559000
195 194817000
Total Noncurrent Liabilities
n/a
13 12783000
14 13786000
32 32474000
283 282621000
353 353188000
293 293204000
4,130 4129650000
Total Liabilities
n/a
98 98045000
152 152301000
260 260259000
643 642710000
936 935617000
900 899944000
4,839 4839265000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
1,094 1093938000
1,173 1173486000
1,262 1261608000
1,852 1852241000
2,106 2106203000
2,592 2592187000
7,727 7726583000
Common Stock
n/a
0 5000
0 18000
0 19000
0 20000
0 20000
0 20000
0 23000
Additional Paid in Capital
n/a
1,094 1093933000
1,173 1173468000
1,262 1261589000
1,852 1852221000
2,106 2106183000
2,592 2592167000
7,727 7726560000
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
-3 -2676000
-3 -2676000
-3 -2676000
-14 -14229000
-80 -80365000
-383 -382964000
-711 -710663000
Retained Earnings
n/a
-401 -400964000
-304 -303934000
-129 -128619000
126 126203000
379 379098000
1,036 1036010000
1,180 1180395000
Other Equity
n/a
-2 -1942000
-7 -7140000
4 4179000
7 6635000
-23 -22857000
57 56785000
62 62301000
Equity Before Minority Interest
n/a
688 688356000
860 859736000
1,134 1134492000
1,971 1970850000
2,382 2382079000
3,302 3302018000
8,259 8258616000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
688 688356000
860 859736000
1,134 1134492000
1,971 1970850000
2,382 2382079000
3,302 3302018000
8,259 8258616000
Total Liabilities & Equity
n/a
786 786401000
1,012 1012037000
1,395 1394751000
2,614 2613560000
3,318 3317696000
4,202 4201962000
13,098 13097881000
Remarks restated on n/a restated on Feb 17, 2011 n/a restated on Feb 17, 2012 n/a restated on Feb 19, 2013 n/a restated on Feb 10, 2014 n/a restated on Feb 6, 2015 n/a restated on Feb 8, 2016 n/a restated on Jul 29, 2016 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '08FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net Income/Starting Line
33
295
97
175
255
253
657
144
Net Income
0
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Depreciation & Amortization
8
12
16
18
24
29
47
167
Non-Cash Items
24
-180
75
94
146
106
-221
779
Stock-Based Compensation
0
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
0
Change in Working Capital
-12
-14
-27
-17
-14
110
157
-415
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
0
Cash from Operating Activities
53
114
161
270
411
497
640
675
Change in Fixed Assets & Intangibles
-40
-35
-13
-22
-22
-29
-137
-286
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Net Change in Long Term Investment
1
-47
-76
94
0
-988
-86
635
Decrease in Long Term Investment
0
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
-106
-606
0
0
-3,939
Net Cash from Divestitures
0
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
0
Other Investing Activities
0
1
0
0
0
-9
-1
5
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
0
Cash from Investing Activities
-39
-81
-89
-34
-628
-1,027
-223
-3,585
Dividends Paid
0
0
0
0
0
0
0
0
Cash From (Repayment of) Debt
0
-44
0
0
149
-36
-56
3,399
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
29
31
38
36
517
5
-188
-246
Increase in Capital Stock
0
0
0
0
0
0
0
0
Decrease in Capital Stock
0
0
0
0
0
0
0
0
Other Financing Activities
0
-1
1
3
0
102
251
-168
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
0
Cash from Financing Activities
28
-14
39
39
666
72
7
2,985
Net Cash Before Disc. Operations and FX
43
18
110
275
449
-458
424
75
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
0
Net Cash Before FX
43
18
110
275
449
-458
424
75
Effect of Foreign Exchange Rates
0
1
0
-2
-1
-1
-10
-9
Net Changes in Cash
43
19
110
274
449
-460
414
66
Remarks
restated on Feb 17, 2011 n/a
calculated values,
restated on Feb 17, 2012 n/a
calculated values,
restated on Feb 19, 2013 n/a
calculated values,
restated on Feb 10, 2014 n/a
calculated values,
restated on Feb 6, 2015 n/a
calculated values,
restated on Feb 8, 2016 n/a
calculated values,
restated on Feb 8, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo